Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 15, 2013. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 292,000 Ordinary Shares of 25 pence each.
- Purchase Date: May 15, 2013.
- Price Range: Highest price paid was 1,720.0 pence per share; lowest price paid was 1,692.5 pence per share.
- Treasury Holdings (Settled): 498,431,327 shares (9.19% of total issued share capital).
- Treasury Holdings (Including Unsettled): 499,316,327 shares (10.14% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,926,338,879 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 292,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.14% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure under the Financial Services Authority's Disclosure and Transparency Rules regarding share ownership thresholds.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (498,431,327 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.14% held in Treasury including unsettled shares) for disclosure threshold assessments.
- Check the price paid per share (1,692.5 to 1,720.0 pence) against market trading data for May 15, 2013.
- Review the total issued share capital excluding Treasury (4,926,338,879) to ensure accurate denominator usage for shareholder notifications.